Betulinic acid and the pharmacological effects of tumor suppression (Review)

Molecular Medicine Reports

Volumn 14, Issue 5, 2016, Pages 4489-4495

  Zhang, Xia ^a   Hu, Jingyu ^a   Chen, Yan ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Antitumor pharmacological effects; Betulinic acid; Cell cycle; Hematological malignancies; Mitochondrial pathway; Solid tumor

Indexed keywords

ANTINEOPLASTIC AGENT; BETULIC ACID; CYCLIN D1; DNA TOPOISOMERASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LAMIN B; LAMIN B1; PENTACYCLIC TRITERPENE; PROTEIN P53; SAPONIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; TRITERPENE; TUMOR PROTEIN;

ACUTE LEUKEMIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BARK; BLADDER CANCER; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL DEATH; COLORECTAL CARCINOMA; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HEAD AND NECK CARCINOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LUNG CARCINOMA; LYMPHOMA; MELANOMA; METASTASIS; METASTASIS INHIBITION; MITOCHONDRION; MULTIPLE MYELOMA; NONHUMAN; PANCREAS CANCER; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR CELL; TUMOR INVASION; UTERINE CERVIX CANCER; BIOSYNTHESIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEMATOLOGIC NEOPLASMS; PATHOLOGY;

GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOLOGIC NEOPLASMS; HUMANS; MITOCHONDRIA; NEOPLASM PROTEINS; SIGNAL TRANSDUCTION; TRITERPENES;

EID: 84992316024     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2016.5792     Document Type: Review

References (84)

1. Gheorgheosu D, Duicu O, Dehelean C, Soica C and Muntean D: Betulinic acid as a potent and complex antitumor phytochemical: A minireview. Anticancer Agents Med Chem 14: 936-945, 2014.
2. Dehelean CA, Soica C, Ledeti I, Aluas M, Zupko I, G Lucan A, Cinta-Pinzaru S and Munteanu M: Study of the betulin enriched birch bark extracts effects on human carcinoma cells and ear inflammation. Chem Cent J 6: 137, 2012.
3. Csuk R: Betulinic acid and its derivatives: A patent review (2008-2013). Expert Opin Ther Pat 24: 913-923, 2014.
4. Jeremias I, Steiner HH, Benner A, Debatin KM and Herold-Mende C: Cell death induction by betulinic acid, ceramide and TRAIL in primary glioblastoma multiforme cells. Acta Neurochir (Wien) 146: 721-729, 2004.
5. Hsu TI, Wang MC, Chen SY, Huang ST, Yeh YM, Su WC, Chang WC and Hung JJ: Betulinic acid decreases specificity protein 1 (Sp1) level via increasing the sumoylation of sp1 to inhibit lung cancer growth. Mol Pharmacol 82: 1115-1128, 2012.
6. Tiwari R, Puthli A, Balakrishnan S, Sapra BK and Mishra KP: Betulinic acid-induced cytotoxicity in human breast tumor cell lines MCF-7 and T47D and its modification by tocopherol. Cancer Inves 32: 402-408, 2014.
7. Jung GR, Kim KJ, Choi CH, Lee TB, Han SI, Han HK and Lim SC: Effect of betulinic acid on anticancer drug-resistant colon cancer cells. Basic Clin Pharmacol Toxicol 101: 277-285, 2007.
8. Rabi T, Shukla S and Gupta S: Betulinic acid suppresses constitutive and TNFalpha-induced NF-kappaB activation and induces apoptosis in human prostate carcinoma PC-3 cells. Mole Carcinog 47: 964-973, 2008.
9. Gao Y, Jia Z, Kong X, Li Q, Chang DZ, Wei D, Le X, Suyun H, Huang S, Wang L, et al: Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion and angiogenesis. Cancer Res 71: 5182-5193, 2011.
10. Soica C, Danciu C, Savoiu-Balint G, Borcan F, Ambrus R, Zupko I, Bojin F, Coricovac D, Ciurlea S, Avram S, et al: Betulinic acid in complex with a gamma-cyclodextrin derivative decreases proliferation and in vivo tumor development of non-metastatic and metastatic B164A5 cells. Int J Mol Sci 15: 8235-8255, 2014.
11. Mullauer FB, Kessler JH and Medema JP: Betulinic acid, a natural compound with potent anticancer effects. Anticancer Drugs 21: 215-227, 2010.
12. Mullauer FB, Kessler JH and Medema JP: Betulinic acid induces cytochrome c release and apoptosis in a Bax/Bak-independent, permeability transition pore dependent fashion. Apoptosis 14: 191-202, 2009.
13. Gibellini L, Pinti M, Nasi M, De Biasi S, Roat E, Bertoncelli L and Cossarizza A: Interfering with ROS metabolism in cancer cells: The potential role of quercetin. Cancers 2: 1288-1311, 2010.
14. Tan Y, Yu R and Pezzuto JM: Betulinic acid-induced programmed cell death in human melanoma cells involves mitogen-activated protein kinase activation. Clin Cancer Res 9: 2866-2875, 2003.
15. Mizushima N: Methods for monitoring autophagy using GFP-LC3 transgenic mice. Methods Enzymol 452: 13-23, 2009.
16. Pathi SS, Jutooru I, Chadalapaka G, Sreevalsan S, Anand S, Thatcher GR and Safe S: GT-094, a NO-NSAID, inhibits colon cancer cell growth by activation of a reactive oxygen species-microRNA-27a: ZBTB10-specificity protein pathway. Mol Cancer Res 9: 195-202, 2011.
17. Safe SH, Prather PL, Brents LK, Chadalapaka G and Jutooru I: Unifying mechanisms of action of the anticancer activities of triterpenoids and synthetic analogs. Anticancer Agents Med Chem 12: 1211-1220, 2012.
18. Papineni S, Chintharlapalli S, Abdelrahim M, Lee SO, Burghardt R, Abudayyeh A, Baker C, Herrera L and Safe S: Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met. Carcinogenesis 30: 1193-1201, 2009.
19. Chadalapaka G, Jutooru I, Burghardt R and Safe S: Drugs that target specificity proteins downregulate epidermal growth factor receptor in bladder cancer cells. Mol Cancer Res 8: 739-750, 2010.
20. Yu Y, Zhao Q, Wang Z and Liu XY: Activated STAT3 correlates with prognosis of non-small cell lung cancer and indicates new anticancer strategies. Cancer Chemother Pharmacol 75: 917-922, 2015.
21. Yadav VR, Prasad S, Sung B, Kannappan R and Aggarwal BB: Targeting inflammatory pathways by triterpenoids for prevention and treatment of cancer. Toxins (Basel) 2: 2428-2466, 2010.
22. Shin J, Lee HJ, Jung DB, Jung JH, Lee HJ, Lee EO, Lee SG, Shim BS, Choi SH, Ko SG et al: Suppression of STAT3 and HIF-1 alpha mediates anti-angiogenic activity of betulinic acid in hypoxic PC-3 prostate cancer cells. PLoS One 6: e21492, 2011.
23. Wan Y, Wu YL, Lian LH, Xie WX, Li X, Ouyang BQ, Bai T, Li Q, Yang N and Nan JX: The anti-fibrotic effect of betulinic acid is mediated through the inhibition of NF-kappaB nuclear protein translocation. Chem Biol Interact 195: 215-223, 2012.
24. Chowdhury AR, Mandal S, Mittra B, Sharma S, Mukhopadhyay S and Majumder HK: Betulinic acid, a potent inhibitor of eukaryotic topoisomerase I: Identification of the inhibitory step, the major functional group responsible and development of more potent derivatives. Med Sci Monit 8: BR254-BR265, 2002.
25. Alakurtti S, Makela T, Koskimies S and Yli-Kauhaluoma J: Pharmacological properties of the ubiquitous natural product betulin. Eur J Pharm Sci 29: 1-13, 2006.
26. Bruckner V, Kovacs J and Koczka I: Occurrence of betulinic acid in the bark of the plane tree. J Chem Soc 1: 948-951, 1948.
27. Yogeeswari P and Sriram D: Betulinic acid and its derivatives: A review on their biological properties. Curr Med Chem 12: 657-666, 2005.
28. Chen QH, Liu J, Zhang HF, He GQ and Fu ML: The betulinic acid production from betulin through biotransformation by fungi. Enzyme Microb Tech 45: 175-180, 2009.
29. Pisha E, Chai H, Lee IS, Chagwedera TE, Farnsworth NR, Cordell GA, Beecher CW, Fong HH, Kinghorn AD, Brown DM, et al: Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nat Med 1: 1046-1051, 1995.
30. Zuco V, Supino R, Righetti SC, Cleris L, Marchesi E, Gambacorti-Passerini C and Formelli F: Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells. Cancer Lett 175: 17-25, 2002.
31. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in globocan 2012. Int J Cancer 136: E359-E386, 2015.
32. Gheorgheosu D, Jung M, Ören B, Schmid T, Dehelean C, Muntean D and Brüne B: Betulinic acid suppresses NGAL-induced epithelial-to-mesenchymal transition in melanoma. Biol Chem 394: 773-781, 2013.
33. Potze L, Mullauer FB, Colak S, Kessler JH and Medema JP: Betulinic acid-induced mitochondria-dependent cell death is counterbalanced by an autophagic salvage response. Cell Death Dis 5: e1169, 2014.
34. Williams MM and Cook RS: Bcl-2 family proteins in breast development and cancer: Could Mcl-1 targeting overcome therapeutic resistance? Oncotarget 6: 3519-3530, 2015.
35. Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T and Korsmeyer SJ: BCL-2, BCL-X (L) sequester BH3 domain-only molecules preventing BAX-and BAK-mediated mitochondrial apoptosis. Mol Cell 8: 705-711, 2011.
36. Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI, Adams JM and Huang DC: Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 19: 1294-1305, 2005.
37. Li W, Liu M, Xu YF, Feng Y, Che JP, Wang GC and Zheng JH: Combination of quercetin and hyperoside has anticancer effects on renal cancer cells through inhibition of oncogenic microRNA-27a. Oncol Rep 31: 117-124, 2014.
38. Mertens-Talcott SU, Noratto GD, Li X, Angel-Morales G, Bertoldi MC and Safe S: Betulinic acid decreases ER-negative breast cancer cell growth in vitro and in vivo: Role of Sp transcription factors and microRNA-27a: ZBTB10. Mol Carcinog 52: 591-602, 2013.
39. Liu X, Jutooru I, Lei P, Kim K, Lee SO, Brents LK, Prather PL and Safe S: Betulinic acid targets YY1 and ErbB2 through cannabinoid receptor-dependent disruption of microRNA-27a: ZBTB10 in breast cancer. Mol Cancer Ther 11: 1421-1431, 2012.
40. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 88: 323-331, 1997.
41. Shi M, Liu D, Shen B and Guo N: Helpers of the cellular gatekeeper-miRNAs dance in P53 network. Biochim Biophys Acta 1805: 218-225, 2010.
42. Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2015 CA. Cancer J Clin 65: 5-29, 2015.
43. GBD 2013 Mortality and Causes of Death Collaborators: Global, regional and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: A systematic analysis for the global burden of disease study 2013. Lancet 385: 117-171, 2015.
44. Mullauer FB, van Bloois L, Daalhuisen JB, Ten Brink MS, Storm G, Medema JP, Schiffelers RM and Kessler JH: Betulinic acid delivered in liposomes reduces growth of human lung and colon cancers in mice without causing systemic toxicity. Anticancer Drugs 22: 223-233, 2011.
45. Chintharlapalli S, Papineni S, Lei P, Pathi S and Safe S: Betulinic acid inhibits colon cancer cell and tumor growth and induces proteasome-dependent and-independent downregulation of specificity proteins (Sp) transcription factors. BMC Cancer 11: 371, 2011.
46. Lai Y, Zhang X, Zhang Z, Shu Y, Luo X, Yang Y, Wang X, Yang G, Li L and Feng Y: The microRNA-27a: ZBTB10-specificity protein pathway is involved in follicle stimulating hormone-induced VEGF, Cox2 and survivin expression in ovarian epithelial cancer cells. Int J Oncol 42: 776-784, 2013.
47. Jutooru I, Chadalapaka G, Lei P and Safe S: Inhibition of NFkappaB and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulation. J Biol Chem 285: 25332-25344, 2010.
48. Jutooru I, Chadalapaka G, Abdelrahim M, Basha MR, Samudio I, Konopleva M, Andreeff M and Safe S: Methyl 2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate decreases specificity protein transcription factors and inhibits pancreatic tumor growth: Role of microRNA-27a. Mol Pharmacol 78: 226-236, 2010.
49. Yang LJ, Chen Y, Ma Q, Fang J, He J, Cheng YQ and Wu QL: Effect of betulinic acid on the regulation of Hiwi and cyclin B1 in human gastric adenocarcinoma AGS cells. Acta Pharmacol Sin 31: 66-72, 2010.
50. Yuan P, Wang L, Wei D, Zhang J, Jia Z, Li Q, Le X, Wang H, Yao J and Xie K: Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer. Cancer 110: 2682-2690, 2007.
51. Dvorak HF: Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20: 4368-4380, 2002.
52. Dittmer TA and Misteli T: The lamin protein family. Genome Biol 12: 222, 2011.
53. Broers JL, Ramaekers FC, Bonne G, Yaou RB and Hutchison CJ: Nuclear lamins: Laminopathies and their role in premature ageing. Physiol Rev 86: 967-1008, 2006.
54. Broers JL, Raymond Y, Rot MK, Kuijpers H, Wagenaar SS and Ramaekers FC: Nuclear A-type lamins are differentially expressed in human lung cancer subtypes. Am J Pathol 143: 211-220, 1993.
55. Moss SF, Krivosheyev V, de Souza A, Chin K, Gaetz HP, Chaudhary N, Worman HJ and Holt PR: Decreased and aberrant nuclear lamin expression in gastrointestinal tract neoplasms. Gut 45: 723-729, 1999.
56. Coradeghini R, Barboro P, Rubagotti A, Boccardo F, Parodi S, Carmignani G, D'Arrigo C, Patrone E and Balbi C: Differential expression of nuclear lamins in normal and cancerous prostate tissues. Oncol Rep 15: 609-613, 2006.
57. Lim SO, Park SJ, Kim W, Park SG, Kim HJ, Kim YI, Sohn TS, Noh JH and Jung G: Proteome analysis of hepatocellular carcinoma. Biochem Biophys Res Commun 291: 1031-1037, 2002.
58. Maeno H, Sugimoto K and Nakajima N: Genomic structure of the mouse gene (Lmnb1) encoding nuclear lamin B1. Genomics 30: 342-346, 1995.
59. Lin F and Worman HJ: Expression of nuclear lamins in human tissues and cancer cell lines and transcription from the promoters of the lamin A/C and B1 genes. Exp Cell Res 236: 378-384, 1997.
60. Li L, Du Y, Kong X, Li Z, Jia Z, Cui J, Gao J, Wang G and Xie K: Lamin B1 is a novel therapeutic target of betulinic acid in pancreatic cancer. Clin Cancer Res 19: 4651-4661, 2013.
61. Sun S, Xu MZ, Poon RT, Day PJ and Luk JM: Circulating Lamin B1 (LMNB1) biomarker detects early stages of liver cancer in patients. J Proteome Res 9: 70-78, 2010.
62. Karna E, Szoka L and Palka JA: Betulinic acid inhibits the expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in human endometrial adenocarcinoma cells. Mol Cell Biochem 340: 15-20, 2010.
63. Gleadle JM and Ratcliffe PJ: Induction of hypoxia-inducible factor-1, erythropoietin, vascular endothelial growth factor and glucose transporter-1 by hypoxia: Evidence against a regulatory role for Src kinase. Blood 89: 503-509, 1997.
64. Van Waes C: Nuclear factor-kappaB in development, prevention and therapy of cancer. Clin Cancer Res 13: 1076-1082, 2007.
65. Patel HM, Rane R, Thapliyal N, Palkar M, Shaikh M and Karpoormath R: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors from the natural origin: A recent perspective. Anticancer Agents Med Chem 15: 988-1011, 2015.
66. Nikiforov YE: RET/PTC rearrangement in thyroid tumors. Endocr Pathol 13: 3-16, 2002.
67. Nikiforov YE and Nikiforova MN: Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 7: 569-580, 2011.
68. Wada S and Tanaka R: Betulinic acid and its derivatives, potent DNA topoisomerase II inhibitors, from the bark of Bischofia javanica. Chem Biodivers 2: 689-694, 2005.
69. Ganguly A, Das B, Roy A, Sen N, Dasgupta SB, Mukhopadhayay S and Majumder HK: Betulinic acid, a catalytic inhibitor of topoisomerase I, inhibits reactive oxygen species-mediated apoptotic topoisomerase I-DNA cleavable complex formation in prostate cancer cells but does not affect the process of cell death. Cancer Res 67: 11848-11858, 2007.
70. Dillon LW, Pierce LC, Lehman CE, Nikiforov YE and Wang YH: DNA topoisomerases participate in fragility of the oncogene RET. PLoS One 8: e75741, 2013.
71. Kommera H, Kaluderovic GN, Kalbitz J and Paschke R: Synthesis and anticancer activity of novel betulinic acid and betulin derivatives. Arch Pharm (Weinheim) 343: 449-457, 2010.
72. Bache M, Bernhardt S, Passin S, Wichmann H, Hein A, Zschornak M, Kappler M, Taubert H, Paschke R and Vordermark D: Betulinic acid derivatives NVX-207 and B10 for treatment of glioblastoma-an in vitro study of cytotoxicity and radiosensitization. Int J Mol Sci 15: 19777-19790, 2014.
73. Engelman JA: Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. Nat Rev Cancer 9: 550-562, 2009.
74. Shaw RJ and Cantley LC: Ras, PI (3)K and mTOR signalling controls tumour cell growth. Nature 441: 424-430, 2006.
75. Madge LA, Li JH, Choi J and Pober JS: Inhibition of phosphatidylinositol 3-kinase sensitizes vascular endothelial cells to cytokine-initiated cathepsin-dependent apoptosis. J Biol Chem 278: 21295-21306, 2003.
76. Gonzalez P, Mader I, Tchoghandjian A, Enzenmuller S, Cristofanon S, Basit F, Debatin KM and Fulda S: Impairment of lysosomal integrity by B10, a glycosylated derivative of betulinic acid, leads to lysosomal cell death and converts autophagy into a detrimental process. Cell Death Differ 19: 1337-1346, 2012.
77. Pandey MK, Sung B and Aggarwal BB: Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells. Int J Cancer 127: 282-292, 2010.
78. Yang LJ, Chen Y, He J, Yi S, Wen L, Zhao J, Zhang BP and Cui GH: Betulinic acid inhibits autophagic flux and induces apoptosis in human multiple myeloma cells in vitro. Acta Pharmacol Sin 33: 1542-1548, 2012.
79. Cheng YQ, Chen Y, Wu QL, Fang J and Yang LJ: Effect of betulinic acid on inducing apoptosis of human multiple myeloma cell line RPMI-8226. Zhongguo Shi Yan Xue Ye Xue Za Zhi 17: 1224-1229, 2009 (In Chinese).
80. Ehrhardt H, Fulda S, Fuhrer M, Debatin KM and Jeremias I: Betulinic acid-induced apoptosis in leukemia cells. Leukemia 18: 1406-1412, 2004.
81. Kumar D, Mallick S, Vedasiromoni JR and Pal BC: Anti-leukemic activity of Dillenia indica L. fruit extract and quantification of betulinic acid by HPLC. Phytomedicine 17: 431-435, 2010.
82. Wu Q, He J, Fang J and Hong M: Antitumor effect of betulinic acid on human acute leukemia K562 cells in vitro. J Huazhong Univ Technolog Med Sci 30: 453-457, 2010.
83. Chen Z, Wu Q, Chen Y and He J: Effects of betulinic acid on proliferation and apoptosis in Jurkat cells and its in vitro mechanism. J Huazhong Univ Sci Technolog Med Sci 28: 634-638, 2008.
84. Chen Z, Wu QL, Chen Y and He J: Effect of betulinic acid on proliferation, apoptosis, and cell cycle of human lymphoma cell line Raji. Zhong Cao Yao Bian Ji Bu 4: 556-559, 2008.